Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus medication litifilimab. In return, Royalty Pharma will receive undisclosed ...

Sage Therapeutics has brought a lawsuit against ... to with Biogen,” a Sage spokesperson said in a statement to Fierce Pharma. The two firms joined hands in late 2020 when Biogen signed on ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...

Sage's board concluded the proposal "significantly ... Biogen,” a Sage spokesperson confirmed in a statement to Fierce Pharma last week. In the companies' original pact, Biogen agreed not ...

Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00.

Sage Therapeutics has a unique approach to targeting ... there’s a trend of recent CNS drugs being acquired by other big pharma companies in the sector. It could also be simply that BIIB saw ...